Literature DB >> 17605969

How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults.

Arif H Kamal1, Ayalew Tefferi, Rajiv K Pruthi.   

Abstract

The prothrombin time (PT) and activated partial thromboplastin time (APTT) are among the most commonly ordered coagulation tests. In 2005, more than 140,000 PT and more than 95,000 APTT tests were performed at Mayo Clinic. The most common indications for ordering these tests include anticoagulant monitoring, initial evaluation of hemorrhage, and, although not generally indicated, routine preoperative screening. In addition, the bleeding time (BT) test, which is infrequently performed, is still available in certain institutions. Abnormal results from these tests (prolonged PT, APTT, and BT), especially from tests conducted for initial evaluation of hemorrhage or for preoperative screening, may pose a diagnostic dilemma to the nonhematologist. We review the essential factors affecting test results; provide a practical approach to the evaluation of a prolonged PT, APTT, and BT; and offer suggestions on which reflexive tests are appropriate and when to consider a subspecialty consultation.

Entities:  

Mesh:

Year:  2007        PMID: 17605969     DOI: 10.4065/82.7.864

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  58 in total

Review 1.  Transfusion and coagulation management in major obstetric hemorrhage.

Authors:  Alexander J Butwick; Lawrence T Goodnough
Journal:  Curr Opin Anaesthesiol       Date:  2015-06       Impact factor: 2.706

2.  Erythrocytosis as a cause of false increase in prothrombin time and activated partial thromboplastin time.

Authors:  K G Sajith; Ashish Goel; Jeyamani Ramachandran; Shenbaga Priya; Sukesh C Nair; C E Eapen
Journal:  Indian J Gastroenterol       Date:  2013-09

3.  What should be the laboratory approach against isolated prolongation of a activated partial thromboplastin time?

Authors:  Mesude Falay; Mehmet Senes; Dogan Yücel; Turan Turhan; Simten Dagdaş; Melike Pekin; Namik K Nazaroglu; Gülsüm Özet
Journal:  J Clin Lab Anal       Date:  2018-02-27       Impact factor: 2.352

4.  Relative safety of 4 weeks of blood flow-restricted resistance exercise in young, healthy adults.

Authors:  B C Clark; T M Manini; R L Hoffman; P S Williams; M K Guiler; M J Knutson; M L McGlynn; M R Kushnick
Journal:  Scand J Med Sci Sports       Date:  2010-03-11       Impact factor: 4.221

5.  Cerebellar hemorrhage as a first presentation of acquired Hemophilia A.

Authors:  Dejan Micic; Eliot C Williams; Joshua E Medow
Journal:  Neurocrit Care       Date:  2011-08       Impact factor: 3.210

Review 6.  Enhanced elimination of dabigatran through extracorporeal methods.

Authors:  Nadia I Awad; Luigi Brunetti; David N Juurlink
Journal:  J Med Toxicol       Date:  2015-03

7.  Elevated International Normalized Ratio Is Associated With Ruptured Aneurysms.

Authors:  Anil Can; Victor M Castro; Dmitriy Dligach; Sean Finan; Sheng Yu; Vivian Gainer; Nancy A Shadick; Guergana Savova; Shawn Murphy; Tianxi Cai; Scott T Weiss; Rose Du
Journal:  Stroke       Date:  2018-09       Impact factor: 7.914

8.  Hemostatic function and transfusion efficacy of apheresis platelet concentrates treated with gamma irradiation in use for thrombocytopenic patients.

Authors:  Mei Zhu; Wei Xu; Bao-Long Wang; Hong Su
Journal:  Transfus Med Hemother       Date:  2014-05-22       Impact factor: 3.747

9.  A dyspnea patient with abnormal prolonged prothrombin time and activated partial thromboplstin time, but without bleeding symptoms.

Authors:  Zhi-de Hu; Bing Gu; An-Mei Deng
Journal:  J Thorac Dis       Date:  2012-04-01       Impact factor: 2.895

10.  Building an immune-mediated coagulopathy consensus: early recognition and evaluation to enhance post-surgical patient safety.

Authors:  Paul Ness; Michael Creer; George M Rodgers; Joseph J Naoum; Kenneth Renkens; Stacy A Voils; W Allan Alexander
Journal:  Patient Saf Surg       Date:  2009-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.